New Webinar on Integrating DoE Tools and ambr® 15 Micro Bioreactors

Featuring a Case Study Showing how this Combined Technology can Reduce Timelines for Process Optimization

Sartorius Stedim Biotech (SSB) today announced that it will be presenting a new bioprocess webinar on Wednesday, March 18th at 9am GMT (10am CET / 2.30pm IST/ 5pm China Standard Time) and again at 4pm GMT (8am PST/11am EST). The live events will detail how to use the new ambr® 15 automated micro bioreactor system with integrated BioPAT® MODDE Software for Design of Experiments (DoE) to make bioprocess optimisation both quicker and easier.

Bioprocessing expert, Dr Barney Zoro, ambr 15 Product Manager at SSB, will introduce the ambr 15 system and its use as an automated small scale cell culture mimic, as well as provide an overview of the integrated BioPAT MODDE Software.

During the 40 minute webinar, Zoro will describe the functional features of the ambr 15 system with its multiple single-use micro bioreactors (10-15mL), controlled by an automated workstation. He will then outline how the BioPAT MODDE software has been integrated into the ambr 15 system to enable users to rapidly generate DoE experiments via work packets and configure each micro bioreactor with its own DoE defined bioprocessing parameters. Zoro will then demonstrate how this can accelerate process development to larger single-use BIOSTAT® pilot and manufacturing scale bioreactors using a DoE case study.

To register for these live webinars, scientists can visit: http://www.tapbiosystems.com/ambr_webinar/ambrdoe_webinarpr.htm

Dr Barney Zoro, ambr15 Product Manager at SSB stated: "Many scientists across the biopharm industry are successfully using the ambr 15 system to speed up their process development. Integrating the BioPAT MODDE Software into the ambr 15 will allow these scientists to rapidly implement DoE into their work flow and I am delighted to be hosting a webinar to discuss this exciting advance.”

Zoro added: “I look forward to explaining how these combined technologies can reduce timelines for process optimisation and scale-up, ensuring more cost-effective manufacturing of biologics and vaccines.”